Advertisement

European Journal of Clinical Pharmacology

, Volume 65, Issue 3, pp 315–318 | Cite as

An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results

  • Ola P. Hole
  • Sigurd Nitter-Hauge
  • Henrik R. Cederkvist
  • Finn Ø. WintherEmail author
Debate Article

Abstract

Objective

In Norway, very little data are available on the relation between the total number of research projects on the clinical development of drugs that have been started, the number of these projects in which the research phase has been completed and the number of projects for which results have been published. The aim of this study was to determine the number of projects in which the research phase had been completed and the results published.

Material and methods

Information on research projects carried out on the clinical development of drugs during the year 2000 was obtained from the archives of the Norwegian Research Ethical Committee (REC) and subsequently analysed.

Results

The final analysis revealed that 245 research projects on the clinical development of drugs had been started in 2000. Of these, 178 (73%) completed the research phase as planned. The results of 131 (54%) of these projects were published in a scientific journal, and another 34 (14%) were reported as a congress abstract or as report to a sponsor; 80 (33%) were not published at all. Industrial sponsors seemed to promote both the completion of the research process and the publication of results in scientific journals.

Keywords

Completion Development of drugs Publication Research projects 

Notes

Acknowledgements

This work was supported by The National Committee for Medical and Health Research Ethics and University of Oslo, Medical Faculty, Division Rikshospitalet.

References

  1. 1.
    Hole OP, Winther FO, Straume B (2001) Clinical research: the influence of the pharmaceutical industry. Eur J Clin Pharmacol 56:851–853PubMedCrossRefGoogle Scholar
  2. 2.
    Winther FO, Hole OP, Nitter-Hauge S (2007) An analysis of the clinical developement of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry. Eur J Clin Pharmacol 63:909–912PubMedCrossRefGoogle Scholar
  3. 3.
    World Medical Association Declaration of Helsinki (2004). Ethical principles for medical research involving human subjects. Adopted June 1964; ammended at the 55th WMA General Assembly, TokyoGoogle Scholar
  4. 4.
    Sandaker L, Fjeld B, Reikvam AA et al (2004) Klinisk legemiddelutprøving I Norge – gjennomføring og rapportering er ikke tilfredstillende. Tidsskr Nor Laegeforen 124:2888–2889PubMedGoogle Scholar
  5. 5.
    Winther FO, Hole OP (1997) Scientific quality of clinical research: an analysis of 40 research projects in pharmacology/pharmacotherapy. Eur J Clin Pharmacol 51:351–354PubMedCrossRefGoogle Scholar
  6. 6.
    Salisbury MW (2008) Best biotech places and emerging clusters, Genome Technology June 2008, pp 35-39. Available at: http://www.genome-technology.com/issues/2_15/coverstory/1472

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Ola P. Hole
    • 1
  • Sigurd Nitter-Hauge
    • 1
  • Henrik R. Cederkvist
    • 1
  • Finn Ø. Winther
    • 1
    Email author
  1. 1.Faculty Division RikshospitaletUniversity of OsloOsloNorway

Personalised recommendations